2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. PCSK9

PCSK9

Proprotein convertase subtilisin/kexin type 9

 

PCSK9 Related Products (66):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-155006
    PCSK9-IN-19
    		Inhibitor
    PCSK9-IN-19 (Compound 1) is a PCSK9 inhibitor. PCSK9-IN-19 can be used for research of high LDL-cholesterol levels and prevention of coronary artery disease.
    PCSK9-IN-19
  • HY-148689
    SPC4061
    		Inhibitor
    SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases.
    SPC4061
  • HY-141724
    PCSK9 ligand 1
    		Inhibitor
    PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand. PCSK9 ligand 1 does not affect PCSK9 function.
    PCSK9 ligand 1
  • HY-146084
    PCSK9 modulator-3
    		Modulator
    PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC50 value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia.
    PCSK9 modulator-3
  • HY-130245A
    (R,R)-PCSK9 degrader 1
    		Degrader
    (R,R)-PCSK9 degrader 1 is the isomer of PCSK9 degrader 1 (HY-130245). PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a Ki of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor.
    (R,R)-PCSK9 degrader 1
  • HY-153454
    PCSK9-IN-18
    		Inhibitor
    PCSK9-IN-18 (compound 188) is a potent PCSK9 inhibitor with a KD value of <200 nM.
    PCSK9-IN-18
  • HY-160036
    PCSK9-IN-22
    		Inhibitor
    PCSK9-IN-22 (compound 29) is an orally active inhibitor of PCSK9. PCSK9-IN-22 inhibits the interaction of the protein with LDLR in vivo.
    PCSK9-IN-22
  • HY-161434
    PCSK9-IN-26
    		Inhibitor
    PCSK9-IN-26 (Compound 116) is an PCSK9 inhibitor (IC50 < 1 nM). PCSK9-IN-26 can be used for metabolic research.
    PCSK9-IN-26
  • HY-153391
    PCSK9-IN-14
    		Inhibitor
    PCSK9-IN-14 (compound Ia-8) is a potent PCSK9 inhibitor.
    PCSK9-IN-14
  • HY-161435
    PCSK9-IN-27
    		Inhibitor
    PCSK9-IN-27 (Compound 108) is a PCSK9 inhibitor (IC50: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake.
    PCSK9-IN-27
  • HY-147252A
    Bezeparsen sodium
    		Inhibitor
    Bezeparsen sodium is a PCSK9 synthesis inhibitor.
    Bezeparsen sodium
  • HY-P99552
    Tafolecimab
    		Inhibitor
    Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia.
    Tafolecimab
  • HY-153453
    PCSK9-IN-17
    		Inhibitor
    PCSK9-IN-17 is a PCSK9 inhibitor. PCSK9-IN-17 can be used for the research of cholesterol metabolism (WO2020150474A1, compound 105).
    PCSK9-IN-17
  • HY-163141
    PCSK9-IN-24
    		Inhibitor
    PCSK9-IN-24 (Compound OY3) is a compound that targets PCSK9. PCSK9-IN-24 reduces PCSK9 levels and increases LDL uptake and may be used in atherosclerosis research.
    PCSK9-IN-24
  • HY-N10702
    PCSK9-IN-9
    		Inhibitor
    PCSK9-IN-9 is an isocoumarins of natural origin. PCSK9-IN-9 can inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), IDOL, and SREBP2 mRNA expression. PCSK9-IN-9 inhibits PCSK9 with an IC50 value of 11.9 μM.
    PCSK9-IN-9
  • HY-146085
    PCSK9 modulator-4
    		Modulator
    PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC50 value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia.
    PCSK9 modulator-4
  • HY-153451
    PCSK9-IN-15
    		Inhibitor
    PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia.
    PCSK9-IN-15
  • HY-157434
    PCSK9-IN-23
    		Inhibitor
    PCSK9-IN-23 (compound 5C) is a potent PCSK9 inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression.
    PCSK9-IN-23
  • HY-132897
    PCSK9-IN-2
    		Inhibitor
    PCSK9-IN-2 is a novel small molecule inhibitor of PCSK9-LDLR protein–protein interaction (PPI) with an IC50 value of 7.57 μM.
    PCSK9-IN-2
  • HY-RS10177
    PCSK9 Human Pre-designed siRNA Set A
    		Inhibitor

    PCSK9 Human Pre-designed siRNA Set A contains three designed siRNAs for PCSK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PCSK9 Human Pre-designed siRNA Set A
    PCSK9 Human Pre-designed siRNA Set A